Vol. 18/No. 16 | OncologyLive

FIT Assay Shows Overall Diagnostic Accuracy for CRC

August 19, 2017

Researchers have concluded from an analysis of multiple studies that the fecal immunochemical test has high overall diagnostic accuracy for screening asymptomatic patients at an increased risk for colorectal cancer (CRC) and moderate accuracy for diagnosing advanced neoplasia (AN).

EGFR-Mutant NSCLC Treatment Paradigm on Verge of Disruption

August 18, 2017

Monotherapy with a tyrosine kinase inhibitor is the frontline standard of care for patients with advanced EGFR-mutant non–small cell lung cancer, with 3 currently approved agents: erlotinib, gefitinib, and afatinib.

Testing Picture Is Coming Into Sharper Focus for Familial and Hereditary Prostate Cancer

August 16, 2017

Research into the biology of prostate cancer has resulted in a growing understanding of the molecular drivers of the malignancy, resulting in a rapid evolution of genetic testing that is poised to revolutionize the diagnosis and care of at-risk men as well as those who have the disease.

Precision Medicine Moves Forward, 1 Validated Biomarker at a Time

August 15, 2017

This commentary from Maurie Markman, MD, highlights a critical required component for the development of effective novel antineoplastic strategies through the process widely known as precision cancer medicine.

From Sidelines to Front Lines

March 28, 2017

One of the most gratifying aspects of the current age of discovery in anticancer therapy is the evolution of once-fatal malignancies into chronic diseases. The pace of progress, however, has not been equal across tumor types.

Positive Immunotherapy Signals in TNBC Need Further Study

March 23, 2017

Immune checkpoint inhibitors in triple-negative breast cancer are showing promise, but there must be future research to determine whether these agents can make a difference in this challenging malignancy.

Innovative Immunotherapy Combo Tests IDO Inhibitor in Melanoma Trial

March 20, 2017

Investigators are looking into a novel immunotherapy combination that pairs the first-in-class IDO1 inhibitor epacadostat (INCB024360) with the checkpoint blockade agent pembrolizumab (Keytruda) in patients with unresectable or metastatic melanoma.